Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
3 Total Failure (P. falciparum) Day<br />
42 PCR unadjusted<br />
1 152 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.10, 0.72]<br />
3.1 Asia 1 152 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.10, 0.72]<br />
4 Total Failure (P. falciparum) Day<br />
42 PCR adjusted<br />
1 141 Risk Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 0.81]<br />
4.1 Asia 1 141 Risk Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 0.81]<br />
5 P. vivax parasitaemia 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only<br />
5.1 Mixed P. falciparum and<br />
vivax infection at baseline<br />
1 220 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.67, 2.29]<br />
5.2 P. vivax parasitaemia by<br />
day 28<br />
1 181 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.04, 4.90]<br />
5.3 P. vivax parasitaemia by<br />
day 42<br />
1 170 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.09, 0.74]<br />
6 Serious adverse events (including<br />
deaths)<br />
1 334 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.71]<br />
7 Early vomiting 1 334 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.22, 1.30]<br />
Comparison 4. Dihydroartemisinin-piperaquine vs Artesunate plus sulfadoxine-pyrimethamine<br />
Outcome or subgroup title<br />
No. of<br />
studies<br />
No. of<br />
participants Statistical method Effect size<br />
1 Total Failure (P. falciparum) Day<br />
42 PCR unadjusted<br />
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only<br />
1.1 Oceania 1 215 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.74, 1.45]<br />
2 Total Failure (P. falciparum) Day<br />
42 PCR adjusted<br />
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only<br />
2.1 Oceania 1 161 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.39, 1.51]<br />
3 Total Failure (P. falciparum) Day<br />
28 PCR unadjusted<br />
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only<br />
3.1 Oceania 1 223 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.62, 1.64]<br />
4 Total Failure (P. falciparum) Day<br />
28 PCR adjusted<br />
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only<br />
4.1 Oceania 1 195 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.46, 2.22]<br />
5 P. vivax parasitaemia by day 42 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only<br />
5.1 Participants with P.<br />
falciparum mono-infection at<br />
baseline<br />
1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.32, 0.65]<br />
5.2 Participants with P. vivax<br />
± P. falciparum at baseline<br />
1 75 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.27, 0.79]<br />
<strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria (Review)<br />
Copyright © 2009 <strong>The</strong> <strong>Cochrane</strong> Collaboration. Published by John Wiley & Sons, Ltd.<br />
112